Feds Seek Input on National PrEP Coverage
The federal government is seeking public input concerning whether its Medicare department should cover HIV pre-exposure prophylaxis and PrEP medication nationwide, including a new injectable drug that has been developed. Centers for Medicare and Medicaid Services (CMS) is considering whether it will cover HIV prevention pre-exposure prophylaxis drugs (PrEP) such as Apretude, a prescription injectable given every two months to individuals at risk of contracting HIV. As part of the analysis, CMS seeks comments from the public, particularly those that include scientific evidence. As of 2020, Medicare coverage for PrEP varies by state or county, but the average cost of […]